Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 19, Pages -Publisher
MDPI
DOI: 10.3390/ijms231911939
Keywords
anticancer drugs; preclinical study; pharmacokinetics; pharmacodynamics; drug combination; PBPK; PD modelling; MDM2 inhibitor; MEK inhibitor
Funding
- Adamed Pharma S.A [0058/DW/2018/01/1]
- European Union funds under Measure 1.2 Sectoral R&D Programmes of the Operational Programme Smart Growth 2014-2020 (INNOMED-programme of scientific research and development works for the economic sector in the field of innovative medicine) [POIR/01.02.00-14-31/15]
Ask authors/readers for more resources
The development of in vitro/in vivo translational methods is essential for identifying effective therapeutic strategies. PBPK/PD modelling for drug combinations like siremadlin and trametinib in mouse models helps estimate synergistic dosing schedules and dose levels. This approach allows researchers to extrapolate in vitro and in vivo results to determine efficacious dosing strategies, potentially aiding in the translation of animal models into clinical settings.
The development of in vitro/in vivo translational methods for synergistically acting drug combinations is needed to identify the most effective therapeutic strategies. We performed PBPK/PD modelling for siremadlin, trametinib, and their combination at various dose levels and dosing schedules in an A375 xenografted mouse model (melanoma cells). In this study, we built models based on in vitro ADME and in vivo PK/PD data determined from the literature or estimated by the Simcyp Animal simulator (V21). The developed PBPK/PD models allowed us to account for the interactions between siremadlin and trametinib at PK and PD levels. The interaction at the PK level was described by an interplay between absorption and tumour disposition levels, whereas the PD interaction was based on the in vitro results. This approach allowed us to reasonably estimate the most synergistic and efficacious dosing schedules and dose levels for combinations of siremadlin and trametinib in mice. PBPK/PD modelling is a powerful tool that allows researchers to properly estimate the in vivo efficacy of the anticancer drug combination based on the results of in vitro studies. Such an approach based on in vitro and in vivo extrapolation may help researchers determine the most efficacious dosing strategies and will allow for the extrapolation of animal PBPK/PD models into clinical settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available